Late-Stage Therapeutic Options in Lung Cancer

During a live virtual event, Melissa L. Johnson, MD, discussed how to treat a 73-year-old patient who was recently diagnosed with extensive-stage small cell lung cancer.

Joshua K. Sabari, MD, discusses the trials that showed efficacy for durvalumab and atezolizumab in patients with extensive-stage small cell lung cancer.

Afshin Dowlati, MD, discusses the targeted therapies available for patients with EGFR-mutated late-stage non–small cell lung cancer.

Aparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.

During a live virtual event, Benjamin P. Levy, MD, discussed the results of the IMpower 133 and CASPIAN trials of immunotherapy for patients with extensive-stage small cell lung cancer.

During a live virtual event, Benjamin P. Levy, MD, discussed the case of a patient with non–small cell lung cancer and an EGFR exon 19 deletion. This is the second of two articles based on this event.